NICOTINIC RECEPTOR ANTAGONISTS AND PIOGLITAZONE AS THERAPEUTIC AGENTS FOR COVID-19

A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID- 19, infection by administering nicotinic receptor antagonists and/or PPAR-y agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone syn­ergistically reduces replication of SARS-CoV-2 in virus­infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-??, and TNFa, which have been associated with SARS-CoV-2 infection.Neuroscience, Medical